Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$903.57M |
$13.60
+2.10%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$902.11M |
$12.39
-2.36%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$893.39M |
$19.19
-4.29%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$877.19M |
$4.50
-1.86%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$871.49M |
$14.63
-8.45%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$868.24M |
$8.09
+1.00%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$856.71M |
$12.38
-0.56%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$849.52M |
$72.91
-5.11%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$846.60M |
$8.62
+0.06%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$845.83M |
$10.15
+3.89%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$839.46M |
$19.86
+12.23%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$834.20M |
$2.77
-2.98%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$820.54M |
$14.56
-5.64%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$817.09M |
$19.17
-1.59%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$794.93M |
$8.88
-1.39%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$786.12M |
$28.36
+1.54%
|
|
EMBC
Embecta Corp.
Embecta provides contract manufacturing/partner manufacturing services and potential co-packaging arrangements.
|
$784.30M |
$13.42
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$782.70M |
$11.59
+0.43%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$778.23M |
$8.92
-1.98%
|
|
VIR
Vir Biotechnology, Inc.
Vir is expanding a targeted oncology portfolio around masked T-cell engagers, placing it in Biotech - Oncology.
|
$774.13M |
$5.33
-4.91%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$764.30M |
$1.17
-2.92%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$761.02M |
$14.77
-2.96%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$754.01M |
$6.59
-19.44%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$750.39M |
$31.25
+20.24%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$748.70M |
$2.90
-1.36%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$748.62M |
$11.80
-7.70%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$743.43M |
$55.91
-6.69%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$742.42M |
$12.04
-0.25%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$740.96M |
$7.37
+0.75%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$738.01M |
$4.17
-2.22%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$717.29M |
$8.99
-3.33%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$709.48M |
$9.61
-1.18%
|
|
KE
Kimball Electronics, Inc.
Strategic expansion into Contract Manufacturing Organizations for medical devices aligns with KE's Medical CMO focus.
|
$709.23M |
$28.82
-0.95%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$703.94M |
$13.46
-0.52%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$703.55M |
$22.73
-1.67%
|
Showing page 9 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
